MEDICAMEQ vs ZIMLAB: Stock Comparison

Medicamen Biotech Limited vs Zim Laboratories Limited

Live data: 22 July 2026, 3:07 PM IST • Source: NSE and company filings

Zim Laboratories Limited is the larger company by market capitalisation. Medicamen Biotech Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Zim Laboratories Limited shows a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Medicamen Biotech Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MEDICAMEQ is more favourable on 12 of 13 scored metrics and ZIMLAB on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ZIMLAB is the larger company
₹656 Cr vs ₹336 Cr
P/E Ratio
MEDICAMEQ has a lower P/E
32.07x vs 112.39x
P/B Ratio
MEDICAMEQ has a lower P/B
1.12x vs 2.21x
EPS
MEDICAMEQ has higher earnings per share
₹7.21 vs ₹1.94
Dividend Yield
MEDICAMEQ has a higher dividend yield
0.41% vs 0.02%
Revenue Growth (TTM YoY)
MEDICAMEQ has faster revenue growth
80.2% vs -3.36%
EPS Growth (TTM YoY)
MEDICAMEQ has faster EPS growth
44.7% vs -47.01%
Qtr Sales Growth
MEDICAMEQ has stronger quarterly sales growth
105% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMEDICAMEQZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMEDICAMEQZIMLAB
Live Price₹247.2₹104.91
Day Change-0.68%0.25%
Volume11,24481,241
52-Week High₹447.65₹121.47
52-Week Low₹212.4₹59.31
Distance from 52W High-44.78%-13.63%

Valuation

MetricMEDICAMEQZIMLAB
Market Cap₹336 Cr₹656 Cr
P/E Ratio32.07x112.39x
P/B Ratio1.12x2.21x
EPS₹7.21₹1.94
Book Value₹234.32₹51.77
Dividend Yield0.41%0.02%

Growth

MetricMEDICAMEQZIMLAB
Revenue Growth (TTM YoY)80.2%-3.36%
EPS Growth (TTM YoY)44.7%-47.01%
Qtr Sales Growth105%-12.3%
Qtr Profit Growth59.5%-308%

Profitability & Leverage

MetricMEDICAMEQZIMLAB
ROE3.95%1.97%
ROCE5.43%8.16%
Net Margin5.21%1.56%
Operating Margin9.91%5.72%
Debt to Equity0.17x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMEDICAMEQZIMLAB
Promoter Holding40.46%30.36% 0.01 pp
FII Holding0.07% 0.03 pp0.03% 0.03 pp
DII Holding0.4% 0.4 pp1.33% 1.26 pp
Public Holding59.02% 0.37 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Medicamen Biotech Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.